



Implications of Further Action on the Elijah E. Cummings Lower Drug Costs Now Act

As we look to the 2020 election and forecast how prescription pricing drug reform could take shape if there is a Democratic House, US Senate and White House beginning in 2021, the Elijah E. Cummings Lower Drug Costs Now Act ([H.R. 3](#)) should be viewed as a starting point for all prescription drug pricing reform discussions. This article explores how a Democratic sweep in the upcoming election could affect policymaking around prescription drug pricing and how H.R. 3 would affect specific drugs' pricing.

On December 12, 2019, the US House of Representatives passed the Elijah E. Cummings Lower Drug Costs Now Act ([H.R. 3](#)) by a 230–192 margin (all present Democrats and two Republicans voted for the bill). The bill would, among other things, authorize Medicare to negotiate prices for certain drugs, use international reference pricing, cap out-of-pocket costs for Part D beneficiaries, require manufacturer rebates if Part B or Part D prices increase faster than inflation, and increase insurer and drug manufacturer responsibility for Part D costs.

In H.R. 3 as currently written, the US Department of Health and Human Services (HHS) must negotiate maximum prices for insulin products and, for fiscal year (FY) 2023, at least 25 single-source, brand-name drugs that do not have generic competition and that are among either the 125 drugs that account for the greatest national spending or the 125 drugs that account for the greatest spending under the Medicare prescription drug benefit and Medicare Advantage. Beginning in FY 2024, HHS also must negotiate maximum prices for at least 50 such single-source, brand-name drugs and newly approved single-source, brand-name drugs that meet or exceed a specified price threshold and which HHS determines are likely to meet the spending criteria. The negotiated prices must be offered under both traditional Medicare and Medicare Advantage and may also be offered under private health insurance unless the insurer opts out. (A drug or biologic is generally considered single-source if there is no generic or biosimilar approved and marketed in the United States. All insulins would be eligible for negotiation regardless of generic or biosimilar availability).

The drugs subject to price negotiation would be identified from:

- Covered Part D drugs (the drug must be one of the top 125 covered Part D drugs with the estimated greatest net spending under Medicare Parts C and D);
- Other drugs (the drug must be one of the top 125 drugs for which there was an estimated greatest net spending in the United States); and
- Insulin.

Based on our interpretation of single-source drugs and biologicals as described in the bill, below we provide a list of the top 125 single source, covered Part D (Table 1) and Part B (Table 2) drugs and all insulins (Table 3) by Total 2018 Medicare Spending¹. Of note, the highest Medicare spending drugs would not necessarily be subject to price negotiation. Which drugs would actually be subject to price negotiation would depend upon updated data at the time of implementation (if the bill becomes law) and the Centers for Medicare and Medicaid Services' interpretation of how to select the drugs that will result in

¹ Insulin may be covered under either Part B or Part D depending on the route of administration. As such, there are insulins that appear on all three lists.



the greatest savings as set forth in implementing regulations. The Secretary of HHS appears to have some discretion when selecting drugs under the bill as currently written.

Total Medicare spending does not reflect discounts or rebates, which are a part of net spending. Lists based on net spending may look different. Information on discounts and rebates is not public.

All lists were derived from data on the Medicare Drug Spending Dashboard.²

For more information, please contact [Jessica Roth](#) or [Katie Waldo](#).



Table 1. Top 125 Single Source, Part D Drugs by Total Medicare Spending

Brand Name	Generic Name	Total 2018 Medicare Spending	Total 2018 Dosage Units	Total 2018 Claims	Total 2018 Beneficiaries
Eliquis	Apixaban	\$4,992,184,164	713,809,249	9,091,996	1,646,841
Revlimid	Lenalidomide	\$4,065,088,801	5,829,300	285,930	39,456
Xarelto	Rivaroxaban	\$3,358,810,708	240,480,958	5,896,570	1,050,679
Januvia	Sitagliptin Phosphate	\$3,228,917,720	226,815,826	4,819,533	919,610
Lyrica	Pregabalin	\$2,950,257,661	391,169,522	5,222,362	905,005
Advair Diskus	Fluticasone Propion/Salmeterol	\$2,394,014,929	356,769,179	4,398,707	1,031,076
Humira Pen	Adalimumab	\$2,388,794,497	971,914	394,616	53,684
Lantus Solostar	Insulin Glargine,Hum.Rec.Anlog	\$2,370,490,822	89,307,638	4,475,777	1,050,705
Imbruvica	Ibrutinib	\$1,867,207,013	7,909,014	165,236	21,934
Symbicort	Budesonide/Formoterol Fumarate	\$1,751,221,156	55,342,532	4,265,249	1,039,596
Harvoni	Ledipasvir/Sofosbuvir	\$1,726,263,039	1,525,818	54,502	22,059
Novolog Flexpen	Insulin Aspart	\$1,712,623,585	47,016,576	2,353,586	583,282
Levemir Flextouch	Insulin Detemir	\$1,584,105,950	54,941,914	2,645,315	535,568
Ibrance	Palbociclib	\$1,507,730,890	2,727,307	131,229	20,100
Spiriva	Tiotropium Bromide	\$1,425,533,899	107,565,641	2,553,761	564,704
Trulicity	Dulaglutide	\$1,360,642,452	3,746,576	1,383,713	263,675
Victoza 3-Pak	Liraglutide	\$1,341,681,068	14,452,465	1,112,950	250,182

² <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/index.html>



Brand Name	Generic Name	Total 2018 Medicare Spending	Total 2018 Dosage Units	Total 2018 Claims	Total 2018 Beneficiaries
Lantus	Insulin Glargine, Hum. Rec. Analog	\$1,253,375,347	47,189,702	2,445,913	524,078
Enbrel Sureclick	Etanercept	\$1,247,769,463	996,244	218,062	30,839
Copaxone	Glatiramer Acetate	\$1,208,097,769	3,053,483	185,180	21,757
Humalog Kwikpen U-100	Insulin Lispro	\$1,199,656,304	34,150,477	1,597,441	429,662
Xtandi	Enzalutamide	\$1,182,615,333	12,926,956	111,112	20,193
Latuda	Lurasidone HCl	\$1,172,672,481	26,445,803	832,063	113,411
Breo Ellipta	Fluticasone/Vilanterol	\$1,159,269,758	201,250,123	2,797,723	645,197
Invega Sustenna	Paliperidone Palmitate	\$1,066,610,506	621,951	504,454	62,460
Myrbetriq	Mirabegron	\$1,063,585,890	89,788,096	2,261,383	464,893
Restasis	Cyclosporine	\$1,058,506,138	124,376,680	1,490,996	501,290
Tradjenta	Linagliptin	\$1,043,195,403	76,101,691	1,822,665	322,978
Tecfidera	Dimethyl Fumarate	\$1,019,481,294	8,110,516	119,035	15,723
Jakafi	Ruxolitinib Phosphate	\$925,013,339	4,367,126	75,165	9,163
Pomalyst	Pomalidomide	\$911,338,941	1,143,656	55,953	9,376
Epclusa	Sofosbuvir/Velpatasvir	\$896,454,303	1,022,022	36,786	13,779
Genvoya	Elviteg/Cob/Emtri/Tenof Alafen	\$871,858,538	8,767,189	278,607	32,236
Triumeq	Abacavir/Dolutegravir/Lamivudi	\$764,629,132	8,067,379	258,493	29,120
Linzess	Linaclotide	\$761,658,895	58,160,952	1,510,049	361,089
H.P. Acthar	Corticotropin	\$724,638,119	90,830	11,907	2,475
Oxycontin	Oxycodone HCl	\$711,006,196	73,171,627	1,173,380	155,978
Novolog	Insulin Aspart	\$694,913,262	24,316,865	1,189,463	266,202
Janumet	Sitagliptin Phos/Metformin HCl	\$692,159,592	97,354,713	1,047,444	204,330
Vesicare	Solifenacin Succinate	\$691,720,522	58,475,720	1,376,968	270,564
Invokana	Canagliflozin	\$671,727,314	43,505,156	905,120	185,687
Creon	Lipase/Protease/Amylase	\$668,508,828	117,691,523	680,178	140,196
Jardiance	Empagliflozin	\$668,459,356	43,343,840	930,007	218,254
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	\$666,541,776	99,404,830	1,353,820	311,980
Ranexa	Ranolazine	\$658,259,298	95,010,411	1,157,998	217,989
Renvela	Sevelamer Carbonate	\$654,147,391	109,930,830	422,329	102,872
Tivicay	Dolutegravir Sodium	\$642,056,270	11,459,826	350,220	41,207



Brand Name	Generic Name	Total 2018 Medicare Spending	Total 2018 Dosage Units	Total 2018 Claims	Total 2018 Beneficiaries
Pradaxa	Dabigatran Etexilate Mesylate	\$637,564,816	106,147,690	1,155,893	214,156
Xifaxan	Rifaximin	\$633,453,581	17,427,398	326,738	79,817
Tresiba Flextouch U-200	Insulin Degludec	\$627,964,947	9,910,356	646,109	146,178
Aubagio	Teriflunomide	\$627,062,230	2,633,511	76,549	10,529
Ofev	Nintedanib Esylate	\$618,635,442	3,940,272	66,472	9,834
Enbrel	Etanercept	\$611,605,535	543,772	109,207	15,458
Letairis	Ambrisentan	\$608,195,650	1,906,592	61,854	7,081
Dexilant	Dexlansoprazole	\$601,789,192	65,526,698	1,511,312	283,630
Forteo	Teriparatide	\$599,576,422	432,082	163,241	27,906
Humira	Adalimumab	\$596,366,043	243,722	97,867	14,700
Toujeo Solostar	Insulin Glargine, Hum. Rec. Analog	\$596,026,241	7,252,613	913,242	196,640
Humalog	Insulin Lispro	\$589,288,819	21,939,524	1,159,155	266,569
Stelara*	Ustekinumab	\$582,683,697	53,184	34,048	9,817
Ventolin HFA	Albuterol Sulfate	\$574,608,768	190,039,623	8,886,496	3,383,182
Descovy	Emtricitabine/Tenofovir Alafenam	\$568,751,711	10,078,247	323,072	38,327
Lumigan	Bimatoprost	\$548,708,660	7,623,014	1,819,160	397,274
Vimpat*	Lacosamide	\$545,362,956	56,306,094	659,732	70,497
Levemir	Insulin Detemir	\$538,215,608	18,418,092	1,002,268	195,578
Spiriva Respimat	Tiotropium Bromide	\$529,512,526	5,684,977	1,057,119	278,220
Incruse Ellipta	Umeclidinium Bromide	\$517,467,102	47,075,573	1,303,943	279,259
Combivent Respimat	Ipratropium/Albuterol Sulfate	\$507,498,092	5,360,318	1,042,197	255,277
Entresto	Sacubitril/Valsartan	\$476,575,743	61,501,574	766,812	150,731
Shingrix	Varicella-Zoster Ge/As01b/PF	\$470,758,396	2,918,616	2,917,423	1,887,984
Gilenya	Fingolimod HCl	\$470,215,655	1,764,386	54,389	6,334
Opsumit	Macitentan	\$468,822,598	1,514,763	49,750	6,107
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insulin Asp	\$465,998,078	12,858,197	458,533	92,512



Brand Name	Generic Name	Total 2018 Medicare Spending	Total 2018 Dosage Units	Total 2018 Claims	Total 2018 Beneficiaries
Basaglar Kwikpen U-100	Insulin Glargine, Hum. Rec. Analog	\$465,157,479	21,217,023	1,208,747	274,348
Mavyret	Glecaprevir/Pibrentasvir	\$461,337,391	2,880,456	34,256	15,929
Brilinta	Ticagrelor	\$424,147,175	71,790,959	869,497	194,992
Flovent HFA	Fluticasone Propionate	\$400,675,878	16,941,228	1,161,886	365,478
Travatan Z	Travoprost	\$393,794,154	5,747,954	1,427,042	317,008
Tagrisso	Osimertinib Mesylate	\$387,940,690	770,874	25,319	4,586
Afinitor	Everolimus	\$386,491,663	727,436	25,463	5,544
Proair HFA	Albuterol Sulfate	\$377,179,823	52,302,682	4,873,413	2,075,847
Sprycel	Dasatinib	\$372,249,027	1,133,075	35,094	4,756
Farxiga	Dapagliflozin Propanediol	\$356,573,700	23,136,260	503,347	115,286
Gammagard Liquid	Immun Glob G(IgG)/Gly/IgA Ov50	\$350,677,511	26,271,181	37,528	3,804
Tasigna	Nilotinib HCl	\$346,488,392	2,979,558	31,480	3,966
Abilify Maintena	Aripiprazole	\$345,985,509	165,496	164,803	22,941
Xeljanz XR	Tofacitinib Citrate	\$337,006,420	2,439,257	73,782	12,737
Victoza 2-Pak	Liraglutide	\$333,840,984	3,550,062	473,305	125,487
Atripla	Efavirenz/Emtricit/Tenofovir Df	\$324,568,993	3,520,457	110,418	13,577
Combigan	Brimonidine Tartrate/Timolol	\$324,117,416	9,976,944	1,294,471	284,565
Prezista	Darunavir Ethanolate	\$323,743,517	8,152,519	200,609	23,253
Uloric	Febuxostat	\$321,560,724	30,139,229	666,032	126,444
Cabometyx	Cabozantinib S-Malate	\$320,398,543	560,902	18,093	3,865
Truvada	Emtricitabine/Tenofovir (Tdf)	\$319,666,546	5,635,252	180,404	26,387
Otezla	Apremilast	\$318,273,429	5,809,157	91,021	15,945
Odefsey	Emtricitab/Rilpiviri/Tenof Ala	\$317,347,400	3,516,177	111,039	12,493
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	\$313,769,284	8,847,802	309,230	62,431
Avonex Pen	Interferon Beta-1a	\$313,725,574	45,508	40,587	4,795
Multaq	Dronedarone HCl	\$312,997,928	29,903,159	351,048	68,943
Amitiza	Lubiprostone	\$310,598,412	49,310,338	793,179	175,533
Sensipar	Cinacalcet HCl	\$309,218,698	8,759,640	245,098	41,943



Brand Name	Generic Name	Total 2018 Medicare Spending	Total 2018 Dosage Units	Total 2018 Claims	Total 2018 Beneficiaries
Ingrezza	Valbenazine Tosylate	\$308,166,322	1,492,090	47,473	8,502
Uptravi	Selexipag	\$305,315,458	1,347,110	17,378	2,250
Tresiba Flextouch U-100	Insulin Degludec	\$304,449,262	9,564,673	543,339	137,234
Prolia	Denosumab	\$303,140,911	258,089	254,983	166,460
Invega Trinza	Paliperidone Palmitate	\$299,673,761	102,985	48,066	14,808
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	\$298,283,826	3,003,660	96,415	20,349
Premarin*	Estrogens, Conjugated	\$297,619,962	37,642,431	922,780	336,465
Synthroid	Levothyroxine Sodium	\$289,488,109	324,470,595	5,251,404	1,063,398
Gamunex-C	Immune Globul G/Gly/IgA Avg 46	\$285,491,001	26,289,578	38,250	3,642
Ampyra	Dalfampridine	\$282,304,089	6,411,939	92,967	13,740
Prezcobix	Darunavir/Cobicistat	\$282,037,922	4,614,763	149,253	18,357
Janumet XR	Sitagliptin Phos/Metformin HCl	\$280,197,855	31,569,839	433,159	92,127
Suboxone	Buprenorphine HCl/Naloxone HCl	\$274,605,512	32,823,176	844,300	76,663
Isentress	Raltegravir Potassium	\$273,318,612	10,796,558	172,789	20,850
Bydureon Pen	Exenatide Microspheres	\$270,982,351	1,636,500	300,273	64,729
Avonex	Interferon Beta-1a	\$269,699,741	39,049	35,051	4,203
Chantix	Varenicline Tartrate	\$269,111,194	36,089,295	621,519	259,263
Ninlaro	Ixazomib Citrate	\$268,301,807	79,555	26,564	4,714
Adcirca	Tadalafil	\$266,243,841	3,898,308	64,463	8,976
Advair HFA	Fluticasone Propion/Salmeterol	\$260,118,571	7,031,635	461,839	121,673
Rebif	Interferon Beta-1a/Albumin	\$259,466,654	210,456	33,685	3,761
Androgel	Testosterone	\$258,946,027	31,330,857	257,553	67,049
Adempas	Riociguat	\$256,166,028	2,292,012	26,246	3,192
Gleevec	Imatinib Mesylate	\$254,871,603	1,214,046	24,751	3,620





Table 2. Top 125 Single Source, Part B Drugs by Total Medicare Spending

Brand Name	Generic Name	HCPCS	Total 2018 Medicare Spending	Total 2018 Dosage Units	Total 2018 Claims	Total 2018 Beneficiaries
Eylea	Aflibercept	J0178	\$2,573,938,387	2,730,001	1,228,011	240,910
Keytruda	Pembrolizumab	J9271	\$1,813,727,267	41,818,943	201,492	35,491
Opdivo	Nivolumab	J9299	\$1,715,907,188	69,929,329	239,434	32,846
Rituxan	Rituximab	J9310	\$1,699,302,442	2,091,194	249,835	70,845
Prolia*	Denosumab*	J0897	\$1,416,968,973	84,040,684	1,078,076	533,286
Neulasta	Pegfilgrastim	J2505	\$1,370,995,237	331,288	315,559	88,742
Lucentis	Ranibizumab	J2778	\$1,215,701,656	3,300,831	618,921	123,389
Remicade	Infliximab	J1745	\$1,149,653,207	14,999,597	296,606	52,085
Avastin	Bevacizumab	J9035	\$1,011,988,293	14,351,978	962,028	224,023
Herceptin	Trastuzumab	J9355	\$821,766,302	8,892,366	187,595	20,586
Orencia*	Abatacept*	J0129	\$799,286,087	16,664,951	219,711	26,726
Darzalex	Daratumumab	J9145	\$645,375,454	12,932,359	93,805	9,309
Ocrevus	Ocrelizumab	J2350	\$488,832,130	8,851,591	18,758	9,704
Alimta	Pemetrexed Disodium	J9305	\$471,369,648	7,818,586	83,648	19,306
Fluzone High-Dose 2017-2018*	Flu Vacc TS2017-18(65yr Up)/PF*	90662	\$461,229,754	9,341,592	9,341,367	9,154,064
Velcade	Bortezomib	J9041	\$443,373,929	10,466,991	273,372	20,262
Pevnar 13	Pneumococcal 13-Valent Vaccine	90670	\$432,793,750	2,282,737	2,282,657	2,267,575
Sandostatin Lar Depot	Octreotide Acetate,mi-Spheres	J2353	\$414,142,370	2,386,122	81,407	9,949
Soliris	Eculizumab	J1300	\$395,796,137	1,980,607	16,063	1,161
Xolair	Omalizumab	J2357	\$395,083,351	12,081,242	181,075	17,070
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	J1569	\$378,891,063	9,924,923	121,151	17,633
Cimzia	Certolizumab Pegol	J0717	\$366,371,065	47,813,843	123,583	15,612
Botox*	Onabotulinumtoxina*	J0585	\$348,391,516	60,268,382	326,397	139,884
Simponi Aria	Golimumab	J1602	\$296,770,201	12,923,945	72,688	16,856



Brand Name	Generic Name	HCPCS	Total 2018 Medicare Spending	Total 2018 Dosage Units	Total 2018 Claims	Total 2018 Beneficiaries
Privigen	Immun Glob G(Igg)/Pro/Iga 0-50	J1459	\$274,360,293	8,076,079	90,836	13,725
Perjeta	Pertuzumab	J9306	\$269,991,282	25,713,562	54,325	7,582
Yervoy	Ipilimumab	J9228	\$269,500,417	2,063,100	11,502	4,595
Abraxane	Paclitaxel Protein-Bound	J9264	\$266,320,982	26,171,202	107,894	16,427
Faslodex	Fulvestrant	J9395	\$249,195,364	2,835,416	141,339	18,966
Kyprolis	Carfilzomib	J9047	\$248,150,983	7,918,465	94,992	5,512
Entyvio	Vedolizumab	J3380	\$243,007,131	14,114,303	46,859	8,882
Aranesp (J0881)	Darbepoetin Alfa In Polysorbat	J0881	\$241,282,506	69,203,868	293,395	50,410
Tecentriq	Atezolizumab	J9022	\$240,758,212	3,234,972	25,775	4,896
Tysabri	Natalizumab	J2323	\$234,996,475	13,753,667	46,114	5,623
Bendeke	Bendamustine HCL	J9034	\$233,169,546	10,025,046	55,439	9,870
Actemra	Tocilizumab	J3262	\$229,831,522	52,777,319	96,092	12,767
NPlate	Romiplostim	J2796	\$216,603,978	3,419,867	76,279	4,277
Brovana	Arformoterol Tartrate	J7605	\$211,251,085	22,293,988	372,923	55,484
Somatuline Depot	Lanreotide Acetate	J1930	\$207,099,486	3,893,711	32,564	4,183
Provenge	Sipuleucel-T/Lactated Ringers	Q2043	\$188,526,961	4,785	4,661	1,759
Pneumovax 23	Pneumococcal 23-Val P-Sac Vac	90732	\$186,378,939	1,888,765	1,888,462	1,874,731
Tyvaso*	Treprostinil*	J7686	\$186,163,594	331,398	11,916	1,489
Erbitux	Cetuximab	J9055	\$182,346,364	3,394,946	50,555	6,476
Remodulin	Treprostinil Sodium	J3285	\$174,773,765	2,858,960	10,677	1,194
Octagam	Immun Globg(Igg)/Malt/Iga Ov50	J1568	\$171,666,328	4,874,034	63,435	10,347
Stelara (J3357)	Ustekinumab	J3357	\$153,223,417	933,938	13,506	4,256
Injectafer	Ferric Carboxymaltose	J1439	\$140,612,426	145,773,931	179,302	88,696
Hizentra	Immun Glob G(Igg)/Pro/Iga 0-50	J1559	\$139,013,935	14,353,327	38,464	3,536



Brand Name	Generic Name	HCPCS	Total 2018 Medicare Spending	Total 2018 Dosage Units	Total 2018 Claims	Total 2018 Beneficiaries
Lexiscan	Regadenoson	J2785	\$130,749,115	2,355,275	600,378	594,382
Fluad*	Flu Vacc TS2017(65up)/Mf59c/PF*	90653	\$122,198,205	2,426,031	2,426,033	2,402,213
Nucala	Mepolizumab	J2182	\$118,484,558	4,078,216	39,948	5,563
Adcetris	Brentuximab Vedotin	J9042	\$117,142,528	904,406	6,629	1,429
Perforomist	Formoterol Fumarate	J7606	\$113,660,277	10,313,179	171,323	29,209
Kadcyla	Ado-Trastuzumab Emtansine	J9354	\$113,562,037	4,160,587	15,273	2,331
Synvisc*	Hylan G-F 20*	J7325	\$107,171,714	9,184,760	211,771	127,287
Cyramza	Ramucirumab	J9308	\$100,254,747	1,935,984	14,039	3,070
Jevtana	Cabazitaxel	J9043	\$97,176,724	657,626	11,079	2,618
Gazyva	Obinutuzumab	J9301	\$95,639,692	1,710,556	17,372	3,407
EpiFix, Per Square Centimeter**		Q4131	\$94,451,294	597,985	49,231	11,806
Vectibix	Panitumumab	J9303	\$93,716,501	921,520	17,769	2,747
Emend	Fosaprepitant Dimeglumine	J1453	\$88,616,215	47,385,322	290,404	75,435
Benlysta	Belimumab	J0490	\$84,899,149	2,146,395	25,634	3,278
Empliciti	Elotuzumab	J9176	\$84,704,011	13,537,787	15,199	1,541
Eloctate	Antihemoph.FVIII Rec,fc Fusion	J7205	\$73,071,020	14,673,517	1,999	151
Krystexxa	Pegloticase	J2507	\$72,284,678	36,200	4,322	620
Orthovisc	Hyaluronate Sodium	J7324	\$68,335,698	481,936	359,008	101,859
Euflexxa	Hyaluronate Sodium	J7323	\$67,115,509	466,579	346,097	104,980
Inflectra	Infliximab-Dyyb	Q5103	\$65,048,865	1,021,568	21,514	5,510
Activase*	Alteplase*	J2997	\$64,645,785	833,755	85,724	56,381
Monovisc	Hyaluronate Sodium, Stabilized	J7327	\$63,461,133	80,401	62,174	52,021
Lumizyme	Alglucosidase Alfa	J0221	\$63,025,688	458,078	2,192	126
Feraheme (Q0138)	Ferumoxytol	Q0138	\$61,123,991	68,939,325	127,540	56,133
Fabrazyme	Agalsidase Beta	J0180	\$57,830,844	383,047	4,103	287



Brand Name	Generic Name	HCPCS	Total 2018 Medicare Spending	Total 2018 Dosage Units	Total 2018 Claims	Total 2018 Beneficiaries
Adynovate	Antihemo.FVIII,full Length Peg	J7207	\$55,671,124	11,636,992	1,229	82
Lartruvo	Olaratumab	J9285	\$53,983,579	1,089,499	7,895	1,033
Cyclophosphamide (J9070)	Cyclophosphamide	J9070	\$53,631,973	1,425,756	112,697	29,187
Alprolix	Factor IX Rec, Fc Fusion Protn	J7201	\$53,437,872	11,501,347	1,173	82
Levulan	Aminolevulinic Acid HCL	J7308	\$52,623,539	134,012	119,394	81,315
Halaven	Eribulin Mesylate	J9179	\$51,908,493	515,472	18,456	2,631
Zortress	Everolimus	J7527	\$50,595,895	6,064,485	18,634	2,343
Ozurdex	Dexamethasone	J7312	\$49,657,594	254,933	35,030	17,207
Cuvitru	Immun Glob G(Igg)/Gly/Iga Ov50	J1555	\$49,216,545	3,701,058	9,884	1,002
Xiaflex	Collagenase Clostridium Hist.	J0775	\$47,829,976	1,144,586	12,054	7,601
Novoseven RT	Coagulation Factor VIIA, recomb	J7189	\$47,790,003	10,274,691	1,148	138
Hyqvia	Igg/Hyaluronidase, recombinant	J1575	\$45,755,323	3,314,680	9,106	944
Treanda	Bendamustine HCL	J9033	\$44,821,632	1,632,298	8,697	2,123
Onivyde	Irinotecan Liposomal	J9205	\$43,837,561	1,013,511	7,997	1,608
Benefix	Factor IX Human Recombinant	J7195	\$42,579,319	16,178,400	1,674	229
Flebogamma Dif	Imm Glob G (Igg)/Sorb/Iga 0-50	J1572	\$42,289,694	1,406,132	15,254	2,581
Feiba NF	Anti-Inhibitor Coagulant Comp.	J7198	\$40,862,655	7,277,251	963	185
Neupogen	Filgrastim	J1442	\$40,366,234	43,785,991	87,284	14,841
Zarxio	Filgrastim-Sndz	Q5101	\$39,527,775	60,347,885	124,148	19,404
Nulojix	Belatacept	J0485	\$36,533,957	11,578,054	22,516	2,640
Lemtrada	Alemtuzumab	J0202	\$36,353,455	23,777	1,618	523
Cerezyme	Imiglucerase	J1786	\$35,737,969	1,005,561	2,297	156
Bavencio	Avelumab	J9023	\$33,977,995	429,277	4,641	550



Brand Name	Generic Name	HCPCS	Total 2018 Medicare Spending	Total 2018 Dosage Units	Total 2018 Claims	Total 2018 Beneficiaries
Pulmozyme	Dornase Alfa	J7639	\$31,188,756	680,946	8,508	1,330
Idelvion	Factor IX Recom,albumin Fusion	J7202	\$30,254,471	3,188,089	655	67
Gel-One	Hyaluronate Sod, Cross-Linked	J7326	\$27,889,238	54,353	41,886	35,352
Humate-P	Antihemophilic Factor/VWF	J7187	\$25,947,985	9,742,125	1,557	330
BCG (Tice Strain) (J9031)*	BCG Live*	J9031	\$24,712,788	187,580	182,796	32,922
Vpriv	Velaglucerase Alfa	J3385	\$23,307,503	76,584	1,741	98
Envarsus Xr	Tacrolimus	J7503	\$23,024,146	18,760,620	30,314	3,687
Puraply or puraply am, per square centimeter**		Q4172	\$21,743,533	243,617	9,359	2,915
Mozobil	Plerixafor	J2562	\$19,707,513	73,314	3,029	1,871
Dalvance	Dalbavancin HCL	J0875	\$19,450,574	1,427,227	6,026	3,618
Imlygic	Talimogene Laherparepvec	J9325	\$19,431,788	404,746	2,059	397
Gammaplex*	Immun Glob G(Igg)/Gly/Iga 0-50*	J1557	\$19,208,545	406,976	5,820	1,248
Sustol	Granisetron	J1627	\$18,810,085	4,656,780	47,012	10,557
Invega Sustenna	Paliperidone Palmitate	J2426	\$17,837,988	2,123,160	12,314	2,517
Firmagon	Degarelix Acetate	J9155	\$17,791,225	5,068,674	45,203	13,252
Ventavis	Iloprost Tromethamine	Q4074	\$17,531,151	130,373	811	101
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	J7620	\$17,378,230	131,273,469	1,432,973	465,039
Folotylin	Pralatrexate	J9307	\$17,107,437	71,151	1,372	168
Flublok Quad 2017-2018*	Flu Vac Qv 2017(18yr Up)rcm/PF*	90682	\$17,105,301	348,031	348,015	346,743
Trelstar	Triptorelin Pamoate	J3315	\$16,997,410	60,024	18,675	7,979
Fulphila	Pegfilgrastim-Jmdb	Q5108	\$16,806,704	46,350	3,880	1,723



Brand Name	Generic Name	HCPCS	Total 2018 Medicare Spending	Total 2018 Dosage Units	Total 2018 Claims	Total 2018 Beneficiaries
Flucelvax Quad 2017-2018 (90674)*	Flu Vac QS 17-18(4yr Up)cel/PF*	90674	\$16,619,926	707,689	707,665	700,308
Xeomin	Incobotulinumtoxina	J0588	\$16,462,837	3,407,390	18,941	8,428
Blincyto	Blinatumomab	J9039	\$13,990,405	138,178	1,171	116
Flucelvax Quad 2017-2018 (90756)*	Flu Vac QS 17-18 (4yr Up) CELI*	90756	\$13,413,683	611,265	601,293	598,837
Hemlibra	Emicizumab-Kxwh	Q9995	\$13,303,946	186,648	358	74
Cinqair	Reslizumab	J2786	\$13,060,142	1,446,114	4,946	663
Rixubis	Factor IX Human Recombinant	J7200	\$13,055,249	5,747,441	313	28
Xyntha*	Antihemoph.FVIII,b-Domain Del*	J7185	\$13,053,892	4,048,451	617	66



Table 3. Insulins by Total Medicare Spending

Brand Name	Generic Name	Total 2018 Medicare Spending	Total 2018 Dosage Units	Total 2018 Claims	Total 2018 Beneficiaries
Lantus Solostar	Insulin Glargine,Hum.Rec. Anlog	\$2,370,490,821.50	89,307,638	4,475,777	1,050,705
Novolog Flexpen	Insulin Aspart	\$1,712,623,585.10	47,016,576	2,353,586	583,282
Levemir Flextouch	Insulin Detemir	\$1,584,105,949.80	54,941,914	2,645,315	535,568
Lantus	Insulin Glargine,Hum.Rec. Anlog	\$1,253,375,347.20	47,189,702	2,445,913	524,078
Humalog Kwikpen U-100	Insulin Lispro	\$1,199,656,303.70	34,150,477	1,597,441	429,662
Novolog	Insulin Aspart	\$694,913,262.07	24,316,865	1,189,463	266,202
Tresiba Flextouch U-200	Insulin Degludec	\$627,964,946.53	9,910,356	646,109	146,178
Toujeo Solostar	Insulin Glargine,Hum.Rec. Anlog	\$596,026,240.76	7,252,613	913,242	196,640
Humalog	Insulin Lispro	\$710,755,339.00	21,939,524	1,159,155	266,569
Levemir	Insulin Detemir	\$538,215,607.69	30,174,967	1,113,918	221,399



Brand Name	Generic Name	Total 2018 Medicare Spending	Total 2018 Dosage Units	Total 2018 Claims	Total 2018 Beneficiaries
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insulin Asp	\$465,998,078.48	12,858,197	458,533	92,512
Basaglar Kwikpen U-100	Insulin Glargine, Hum. Rec. Anlog	\$465,157,479.09	21,217,023	1,208,747	274,348
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	\$313,769,283.50	8,847,802	309,230	62,431
Tresiba Flextouch U-100	Insulin Degludec	\$304,449,262.41	9,564,673	543,339	137,234
Humulin 70-30	Insulin NPh Hum/Reg Insulin Hm	\$172,680,049.56	12,929,074	431,973	82,611
Humulin R U-500 Kwikpen	Insulin Regular, Human	\$164,206,982.82	1,758,612	103,132	18,383
Novolin 70-30	Insulin NPh Hum/Reg Insulin Hm	\$163,739,269.55	15,867,130	520,976	104,093
Novolog Mix 70-30	Insulin Aspart Prot/Insulin Asp	\$150,741,064.91	5,133,749	187,759	36,427
Humulin N	Insulin NPh Human Isophane	\$140,364,792.04	17,036,419	517,033	123,319
Humalog Kwikpen U-200	Insulin Lispro	\$122,104,960.80	1,718,290	100,834	27,426
Humulin R U-500	Insulin Regular, Human	\$121,972,052.89	1,656,048	59,370	11,605
Humalog Mix 75-25	Insulin Lispro Protamin/Lispro	\$118,623,121.49	4,104,312	148,524	27,443
Humulin 70/30 Kwikpen	Insulin NPh Hum/Reg Insulin Hm	\$91,546,567.82	3,377,326	119,871	26,049
Novolin N	Insulin NPh Human Isophane	\$82,908,402.52	8,248,029	323,880	71,476
Humulin R	Insulin Regular, Human	\$70,830,115.15	7,011,316	345,886	93,973
Novolin R	Insulin Regular, Human	\$64,723,913.44	5,939,949	325,125	81,977
Humulin N Kwikpen	Insulin NPh Human Isophane	\$52,863,655.43	2,787,155	110,751	29,826
Soliqua 100-33	Insulin Glargine/Lixisenatide	\$33,848,073.86	743,721	43,814	13,040
Humalog Mix 50-50 Kwikpen	Insulin Lispro Protamin/Lispro	\$27,912,797.64	788,934	23,750	5,092



Brand Name	Generic Name	Total 2018 Medicare Spending	Total 2018 Dosage Units	Total 2018 Claims	Total 2018 Beneficiaries
Xultophy 100-3.6	Insulin Degludec/Liraglutide	\$26,768,687.16	405,417	25,212	7,477
Toujeo Max Solostar	Insulin Glargine, Hum. Rec. Anlog	\$18,059,363.24	218,858	16,813	8,613
Apidra Solostar	Insulin Glulisine	\$16,597,054.17	486,128	20,747	6,209
Humalog Mix 50-50	Insulin Lispro Protamin/Lispro	\$13,744,214.22	474,705	14,831	2,601
Apidra	Insulin Glulisine	\$6,875,874.30	260,090	8,865	2,470
Fiasp Flextouch	Insulin Aspart (Niacinamide)	\$5,448,962.04	147,932	6,181	2,786
Afrezza	Insulin Regular, Human	\$4,495,446.24	749,550	4,143	1,135
Fiasp	Insulin Aspart (Niacinamide)	\$2,008,560.85	71,940	2,055	1,000
Humalog Junior Kwikpen	Insulin Lispro	\$1,941,879.52	55,983	3,175	1,550
Admelog Solostar	Insulin Lispro	\$1,124,957.97	36,927	2,995	1,645
Admelog	Insulin Lispro	\$403,661.76	17,019	1,069	658